KR102169216B1 - 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법 - Google Patents

돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법 Download PDF

Info

Publication number
KR102169216B1
KR102169216B1 KR1020207003847A KR20207003847A KR102169216B1 KR 102169216 B1 KR102169216 B1 KR 102169216B1 KR 1020207003847 A KR1020207003847 A KR 1020207003847A KR 20207003847 A KR20207003847 A KR 20207003847A KR 102169216 B1 KR102169216 B1 KR 102169216B1
Authority
KR
South Korea
Prior art keywords
seq
difficile
toxin
amino acid
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207003847A
Other languages
English (en)
Korean (ko)
Other versions
KR20200017552A (ko
Inventor
카트린 우테 얀센
아날리에사 시빌 앤더슨
로버트 지.케이. 도날드
마이클 제임스 핀트
네이렌더 쿠마르 칼리안
제이슨 아놀드 로트빈
만니더 케이 시두
저스틴 케이쓰 모란
마크 에드워드 루펜
웨이퀴앙 선
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20200017552A publication Critical patent/KR20200017552A/ko
Application granted granted Critical
Publication of KR102169216B1 publication Critical patent/KR102169216B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C12R1/145—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207003847A 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법 Active KR102169216B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261716605P 2012-10-21 2012-10-21
US61/716,605 2012-10-21
PCT/IB2013/059183 WO2014060898A2 (en) 2012-10-21 2013-10-07 Compositions and methods relating to a mutant clostridium difficile toxin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197016516A Division KR102078517B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20200017552A KR20200017552A (ko) 2020-02-18
KR102169216B1 true KR102169216B1 (ko) 2020-10-22

Family

ID=49546596

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020207003847A Active KR102169216B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
KR1020197001177A Active KR101990272B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
KR1020197016516A Active KR102078517B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
KR1020157009888A Active KR101751822B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
KR1020177017169A Active KR101940939B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020197001177A Active KR101990272B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
KR1020197016516A Active KR102078517B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
KR1020157009888A Active KR101751822B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
KR1020177017169A Active KR101940939B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법

Country Status (19)

Country Link
US (5) US10787652B2 (enExample)
EP (2) EP2909307B1 (enExample)
JP (4) JP6527661B2 (enExample)
KR (5) KR102169216B1 (enExample)
CN (2) CN108004286B (enExample)
AU (5) AU2013333532C1 (enExample)
BR (2) BR122016023101B1 (enExample)
CA (2) CA3063892C (enExample)
DK (1) DK2909307T3 (enExample)
ES (1) ES2878551T3 (enExample)
HR (1) HRP20211170T1 (enExample)
HU (1) HUE055594T2 (enExample)
IL (3) IL237792B (enExample)
MX (2) MX379863B (enExample)
PL (1) PL2909307T3 (enExample)
PT (1) PT2909307T (enExample)
RU (1) RU2630671C2 (enExample)
SI (1) SI2909307T1 (enExample)
WO (1) WO2014060898A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI815599B (zh) * 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP4079760A3 (en) 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
ES2870506T3 (es) * 2015-02-19 2021-10-27 Immune Biosolutions Inc Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos
KR101723167B1 (ko) * 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR101729251B1 (ko) * 2015-04-28 2017-04-21 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
EP3344276B1 (en) * 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CN106801077A (zh) * 2017-02-13 2017-06-06 江南大学 一种高效杀灭滴虫等医学原虫的细菌培养上清液的制备方法和及其利用
EP3687570A1 (en) * 2017-09-28 2020-08-05 Pfizer Inc Compositions and methods for eliciting an immune response against clostridium difficile
EP3946444A1 (en) 2019-04-01 2022-02-09 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
BR112021023119A2 (pt) * 2019-05-21 2022-01-25 Univ California Composições de vacina para clostridium difficile
WO2021226330A1 (en) * 2020-05-06 2021-11-11 Albert Einstein College Of Medicine Agents to prevent tissue damage from clostridium difficile infections by inhibition of the gut-damaging bacterial toxins tcda and tcdb
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
EP4493153A1 (en) 2022-03-14 2025-01-22 Pfizer Inc. Methods for producing an adjuvant
JP2025541207A (ja) 2022-12-13 2025-12-18 ファイザー・インク クロストリディオイデス（クロストリジウム）・ディフィシル（ｃｌｏｓｔｒｉｄｉｏｉｄｅｓ（ｃｌｏｓｔｒｉｄｉｕｍ）ｄｉｆｆｉｃｉｌｅ）に対する免疫応答を誘発するための免疫原性組成物および方法
WO2025057058A1 (en) 2023-09-13 2025-03-20 Pfizer Inc. Methods for producing an adjuvant
WO2025257712A1 (en) 2024-06-12 2025-12-18 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216123A (ja) 1982-06-10 1983-12-15 Kazue Ueno 抗血清
US4530833A (en) * 1982-09-13 1985-07-23 Wilkins Tracy D Toxins and antibodies of C. difficile
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
EP0154064A1 (en) * 1984-03-02 1985-09-11 Tracy Dale Wilkins Toxins and antibodies of C. difficile
US4713240A (en) 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5599539A (en) 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
AU668092B2 (en) 1991-04-22 1996-04-26 Massachusetts Health Research Institute, Inc. Process of screening plasma samples for effective antibody titers against respiratory viruses
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
ES2199227T5 (es) 1993-03-29 2007-12-01 Pfizer Inc. Vacunas clostridiales multicomponente que usan adyuvantes de saponina.
JPH10505358A (ja) 1994-09-06 1998-05-26 ギャラゲン・インコーポレイテッド クロストリジウム・ディフィシル関連疾患の治療処置
EP0796326A4 (en) 1994-10-24 2000-01-19 Ophidian Pharm Inc VACCINE AND ANTITOXIN FOR THE TREATMENT AND PREVENTION OF C. DIFFICILE DISEASE
US6743430B1 (en) 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
US5610023A (en) 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
WO1997002836A1 (en) 1995-07-07 1997-01-30 Oravax, Inc. Clostridium difficile toxins as mucosal adjuvants
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
EP0877623A1 (en) 1995-07-07 1998-11-18 Oravax, Inc. Intranasal vaccination against gastrointestinal disease
ES2248822T3 (es) 1995-09-15 2006-03-16 Dale N. Gerding Procedimientos y composiciones para la prevencion y el tratamiento de enfermedades asociadas al clostridium difficile.
ES2224273T3 (es) 1996-09-30 2005-03-01 University Of Arkansas Metodo para producir inmunidad activa por medio de un conjugado de vacuna.
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20050106157A1 (en) 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
AU754270B2 (en) 1997-10-20 2002-11-07 Sanofi Pasteur Biologics, Llc Passive immunization against clostridium difficile disease
CA2365915C (en) 1999-04-09 2015-11-24 Techlab, Inc. Recombinant toxin a/toxin b vaccine against clostridium difficile
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
GB0008682D0 (en) 2000-04-07 2000-05-31 Microbiological Res Authority Transformation of clostridium difficile
CZ20023662A3 (cs) 2000-05-04 2003-04-16 President And Fellows Of Harvard College Sloučeniny a způsoby léčení a prevence bakteriální infekce
CA2450783A1 (en) 2001-06-20 2003-01-03 Ramot At Tel Aviv University Ltd. Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
AU2003242024A1 (en) 2002-06-05 2003-12-22 Chugai Seiyaku Kabushiki Kaisha Method of constructing antibody
US7226597B2 (en) 2002-06-17 2007-06-05 The Board Of Regents Of The University Of Oklahoma Mutants of Clostridium difficile toxin B and methods of use
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
US20050020506A1 (en) 2003-07-25 2005-01-27 Drapeau Susan J. Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
US7354740B2 (en) * 2003-09-25 2008-04-08 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
BRPI0506917A (pt) 2004-01-16 2007-06-05 Dow Global Technologies Inc expressão de proteìnas de mamìferos em pseudomonas fluorescens
NZ530709A (en) * 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
PL2857418T3 (pl) * 2004-02-06 2017-10-31 Univ Massachusetts Przeciwciała przeciw toksynom Clostridium difficile i ich zastosowania
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
WO2006130925A1 (en) 2005-06-10 2006-12-14 Monash University Genetic manipulation of clostridium difficile
GB0512751D0 (en) * 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
EP1987361A4 (en) 2006-01-30 2009-03-04 Invitrogen Corp COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES
GB0612301D0 (en) 2006-06-21 2006-08-02 Morvus Technology Ltd DNA molecules and methods
WO2008024769A2 (en) 2006-08-21 2008-02-28 Raven Biotechnologies, Inc. Intensified perfusion production method
PL2124556T3 (pl) * 2006-10-09 2015-02-27 Charleston Laboratories Inc Kompozycje farmaceutyczne
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US9096638B2 (en) 2007-09-06 2015-08-04 Geneohm Sciences Canada, Inc. Detection of toxigenic strains of Clostridium difficile
CN101855336B (zh) 2007-09-14 2019-07-30 赛诺菲巴斯德生物制剂有限责任公司 含艰难梭菌类毒素a和b的药物组合物
WO2009132082A2 (en) 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
WO2009139919A2 (en) 2008-05-15 2009-11-19 Tufts University Methods for diagnosis of clostridium diffcile and methods and vectors for recombinant toxin expression
EP2310045A1 (en) 2008-06-25 2011-04-20 Novartis AG Rapid responses to delayed booster immunisations
EP2146490A1 (en) 2008-07-18 2010-01-20 Alcatel, Lucent User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems
WO2010017383A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
WO2010036826A1 (en) 2008-09-24 2010-04-01 Sanofi Pasteur Biologics Co. Methods and compositions for increasing toxin production
CN102264381B (zh) * 2008-10-01 2014-07-09 美国政府(由卫生和人类服务部的部长所代表) 提供对疟原虫的长效免疫应答的用于疟疾的多组分疫苗
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
KR20110100189A (ko) * 2008-12-03 2011-09-09 베링거잉겔하임베트메디카게엠베하 백신 생산 방법
CA2745096C (en) 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
GB0901001D0 (en) 2009-01-22 2009-03-04 Univ Nottingham Methods
CA2752815A1 (en) 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
JP2013503198A (ja) 2009-08-27 2013-01-31 シナプティック リサーチ，リミテッド ライアビリティ カンパニー 人工多能性幹（ｉＰＳ）細胞または組織特異的細胞を誘導するための新規タンパク質送達系
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
CA2782406A1 (en) 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
BR112012024898A2 (pt) * 2010-03-30 2015-10-06 Pfenex Inc expressão de nível elevado de proteínas recombinantes de toxinas
US8765399B2 (en) * 2010-05-18 2014-07-01 Montefiore Medical Center Cultures and protocols for diagnosis of toxigenic Clostridium difficile
WO2012028418A1 (en) * 2010-09-02 2012-03-08 Novacem Limited Integrated process for producing compositions containing magnesium
CN103957931B (zh) 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
CA2817579A1 (en) 2010-11-12 2012-04-14 Reflexion Pharmaceuticals, Inc. Gb1 peptidic libraries and compounds, and methods of screening the same
CN102533867A (zh) * 2010-12-10 2012-07-04 西北民族大学 一种艰难梭菌a毒素的类毒素的制备方法
TWI815599B (zh) * 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
ES2615737T3 (es) * 2011-05-27 2017-06-08 Glaxosmithkline Biologicals S.A. Composición inmunogénica
US9770500B2 (en) 2011-05-31 2017-09-26 The Board Of Regents Of The University Of Texas System S-nitrosylation of glucosylating toxins and uses therefor
US20150071958A1 (en) * 2011-11-30 2015-03-12 Board Of Trustees Of Michigan State University Immunological composition for clostridium difficile
CN103974718A (zh) 2011-12-08 2014-08-06 诺华股份有限公司 基于艰难梭菌毒素的疫苗
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR112015004629A2 (pt) * 2012-09-19 2017-11-21 Novartis Ag polipeptídeos de clostridium difficile como vacinas
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP2925362A4 (en) * 2012-11-28 2016-07-20 Cnj Holdings Inc ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE
WO2014086787A1 (en) * 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
WO2014144567A2 (en) * 2013-03-15 2014-09-18 Sanofi Pasteur, Inc. Toxoid, compositions and related methods
EP4079760A3 (en) * 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
WO2014165608A1 (en) 2013-04-02 2014-10-09 Stc. Unm Antibiotic protocells and related pharmaceutical formulations and methods of treatment
CN105611942A (zh) 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法
EP3060246A4 (en) * 2013-10-23 2017-08-16 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HK1259103A1 (zh) 2015-11-17 2019-11-22 Pfizer Inc. 用於在细菌细胞培养物中生产多糖的培养基和发酵方法
MA44252A (fr) * 2016-02-16 2018-12-26 Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation
EP3595709A4 (en) 2017-03-15 2020-12-23 Novavax, Inc. METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES TO CLOSTRIDIUM DIFFICILE
US10577665B2 (en) 2017-09-05 2020-03-03 Mcmaster University Aptamers for clostridium difficile detection
EP3687570A1 (en) 2017-09-28 2020-08-05 Pfizer Inc Compositions and methods for eliciting an immune response against clostridium difficile
EP3946444A1 (en) 2019-04-01 2022-02-09 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS, Vol.106, pp.13225-13229(2009.08.11.)

Also Published As

Publication number Publication date
KR20150056843A (ko) 2015-05-27
KR101990272B1 (ko) 2019-06-17
HUE055594T2 (hu) 2021-12-28
AU2021277590A1 (en) 2021-12-23
AU2019203159A1 (en) 2019-05-30
AU2013333532A1 (en) 2015-04-02
KR20200017552A (ko) 2020-02-18
IL237792A0 (en) 2015-05-31
US10787652B2 (en) 2020-09-29
JP7556987B2 (ja) 2024-09-26
IL284582A (en) 2021-08-31
US11208633B2 (en) 2021-12-28
US20210024903A1 (en) 2021-01-28
CA2887891C (en) 2023-03-07
KR101751822B1 (ko) 2017-06-28
AU2019203159B2 (en) 2020-05-07
JP6527661B2 (ja) 2019-06-05
US20150291940A1 (en) 2015-10-15
KR102078517B1 (ko) 2020-02-18
IL284582B (en) 2022-12-01
EP2909307B1 (en) 2021-05-26
ES2878551T3 (es) 2021-11-19
AU2017201193B2 (en) 2019-02-07
JP2021119775A (ja) 2021-08-19
RU2015112079A (ru) 2016-12-10
CA3063892A1 (en) 2014-04-24
CA3063892C (en) 2023-05-09
WO2014060898A3 (en) 2014-06-12
US20250002875A1 (en) 2025-01-02
EP3912990A1 (en) 2021-11-24
IL237792B (en) 2021-03-25
IL284582B2 (en) 2023-04-01
HK1212385A1 (en) 2016-06-10
CA2887891A1 (en) 2014-04-24
MX2019013075A (es) 2019-12-16
BR112015008844A8 (pt) 2018-04-03
KR20190069604A (ko) 2019-06-19
JP2019150045A (ja) 2019-09-12
AU2017201193C1 (en) 2019-10-24
IL271064A (en) 2020-01-30
AU2013333532C1 (en) 2019-10-24
BR122016023101A2 (pt) 2019-08-27
CN108004286A (zh) 2018-05-08
KR20190008988A (ko) 2019-01-25
JP6871969B2 (ja) 2021-05-19
MX369289B (es) 2019-11-04
RU2630671C2 (ru) 2017-09-11
IL271064B (en) 2021-07-29
JP7208293B2 (ja) 2023-01-18
CN104797706A (zh) 2015-07-22
MX2015004986A (es) 2015-07-17
JP2014083054A (ja) 2014-05-12
CN104797706B (zh) 2020-05-26
CN108004286B (zh) 2022-03-08
HK1254448A1 (zh) 2019-07-19
EP2909307A2 (en) 2015-08-26
US10982198B2 (en) 2021-04-20
DK2909307T3 (da) 2021-07-05
US20190112584A1 (en) 2019-04-18
JP2023036952A (ja) 2023-03-14
AU2017201193A1 (en) 2017-03-16
MX379863B (es) 2025-03-11
BR122016023101B1 (pt) 2022-03-22
PL2909307T3 (pl) 2022-11-07
KR20170077263A (ko) 2017-07-05
BR112015008844A2 (pt) 2017-11-21
KR101940939B1 (ko) 2019-01-21
US20200165582A1 (en) 2020-05-28
WO2014060898A2 (en) 2014-04-24
HRP20211170T1 (hr) 2021-11-12
AU2020203423A1 (en) 2020-06-11
PT2909307T (pt) 2021-07-14
BR112015008844B1 (pt) 2022-03-22
US11952597B2 (en) 2024-04-09
SI2909307T1 (sl) 2021-08-31
AU2013333532B2 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
JP7556987B2 (ja) 突然変異クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）毒素に関する組成物および方法
EP3549949B1 (en) Compositions relating to a mutant clostridium difficile toxin and methods thereof
HK1254448B (en) Compositions and methods relating to a mutant clostridium difficile toxin
HK1212385B (zh) 涉及突变型艰难梭菌毒素的组合物和方法
HK1195325A (en) Compositions relating to a mutant clostridium difficile toxin and methods thereof
HK1195325B (en) Compositions relating to a mutant clostridium difficile toxin and methods thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200210

Application number text: 1020197016516

Filing date: 20190610

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200311

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200323

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200908

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20201015

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20201015

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Patent event code: PG17011E01I

Patent event date: 20201110

Comment text: Request for Publication of Correction

Publication date: 20201113

PR1001 Payment of annual fee

Payment date: 20230921

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240925

Start annual number: 5

End annual number: 5